Cara Therapeutics (NASDAQ:CARA) Upgraded at BidaskClub

BidaskClub upgraded shares of Cara Therapeutics (NASDAQ:CARA) from a hold rating to a buy rating in a report published on Saturday, BidAskClub reports.

Other analysts have also recently issued reports about the company. HC Wainwright boosted their price objective on Cara Therapeutics from $26.00 to $28.00 and gave the company a buy rating in a research report on Wednesday, May 29th. Laidlaw boosted their price objective on Cara Therapeutics from $26.00 to $32.00 and gave the company a buy rating in a research report on Wednesday, May 29th. Needham & Company LLC boosted their price objective on Cara Therapeutics from $28.00 to $35.00 and gave the company a buy rating in a research report on Wednesday, May 29th. Finally, Zacks Investment Research upgraded DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $25.31.

Shares of CARA stock opened at $25.42 on Friday. The firm’s 50 day moving average is $20.92. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.40 and a current ratio of 3.40. The stock has a market capitalization of $965.17 million, a PE ratio of -12.34 and a beta of 2.25. Cara Therapeutics has a twelve month low of $12.19 and a twelve month high of $26.60.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01). The company had revenue of $4.38 million for the quarter, compared to analysts’ expectations of $5.14 million. Cara Therapeutics had a negative net margin of 443.71% and a negative return on equity of 67.30%. Research analysts anticipate that Cara Therapeutics will post -2.38 EPS for the current year.

In other news, Director Jeffrey L. Ives sold 2,500 shares of Cara Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.75, for a total value of $54,375.00. Following the sale, the director now directly owns 8,500 shares of the company’s stock, valued at $184,875. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Frederique Ph.D. Menzaghi sold 20,000 shares of Cara Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.90, for a total value of $438,000.00. Following the completion of the sale, the insider now directly owns 128,882 shares in the company, valued at $2,822,515.80. The disclosure for this sale can be found here. Insiders sold 41,921 shares of company stock valued at $905,677 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Several large investors have recently modified their holdings of CARA. TCG Advisors LP acquired a new stake in shares of Cara Therapeutics in the first quarter worth approximately $30,000. Captrust Financial Advisors boosted its stake in shares of Cara Therapeutics by 40.0% in the fourth quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,400 shares during the last quarter. Advisory Services Network LLC boosted its stake in shares of Cara Therapeutics by 39,086.4% in the fourth quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 8,599 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Cara Therapeutics by 67,680.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,778 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,768 shares during the last quarter. Finally, Knott David M acquired a new stake in shares of Cara Therapeutics in the first quarter worth approximately $140,000. 56.10% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Further Reading: What is diluted earnings per share (Diluted EPS)?

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.